Adverum Biotechnologies Inc (ADVM) Scheduled to Post Earnings on Monday
Adverum Biotechnologies Inc (NASDAQ:ADVM) is set to release its earnings data on Monday, November 6th. Analysts expect Adverum Biotechnologies to post earnings of ($0.29) per share for the quarter.
Shares of Adverum Biotechnologies Inc (NASDAQ ADVM) opened at $3.25 on Friday. Adverum Biotechnologies Inc has a 52 week low of $2.40 and a 52 week high of $4.20.
A number of equities analysts have issued reports on the company. ValuEngine downgraded Adverum Biotechnologies from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research downgraded Adverum Biotechnologies from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Chardan Capital reiterated a “hold” rating and set a $3.50 price target on shares of Adverum Biotechnologies in a research report on Tuesday, September 5th. Finally, Raymond James Financial, Inc. assumed coverage on Adverum Biotechnologies in a research report on Thursday, October 12th. They set an “outperform” rating and a $6.00 price target on the stock.
Adverum Biotechnologies Company Profile
Adverum Biotechnologies, Inc, formerly Avalanche Biotechnologies, Inc, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics.
Receive News & Ratings for Adverum Biotechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.